Skip to main content

Table 3 Significantly different values in NK cell subsets in controls (Ctrl) and non-recurrent SCCHN patients

From: Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

%

Ctrl

t0

t1

t2

t3

CD56bright/CD16- NK cells

1.83 ± 1.14

2.48 ± 1.94

1.78 ± 1.65*

2.11 ± 1.55

2.25 ± 1.62

CD56bright/CD16+ NK cells

2.52 ± 1.34

4.72 ± 3.98*

3.72 ± 3.32

3.08 ± 2.15

4.09 ± 2.68

CD56dim/CD16− NK cells

2.8 ± 1.8

3.98 ± 2.82

4.42 ± 3.53

2.32 ± 1.33

7.5 ± 8.53

CD56dim/CD16+

NK cells

87.27 ± 5.97

83.10 ± 10.29

84.93 ± 10.49

89.3 ± 5.46*

82.8 ± 12.27

CD56−/CD16+

NK cells

0 ± 0

0.01 ± 0.02

0.14 ± 0.27

0.05 ± 0.09

0.09 ± 0.16

  1. The significance is between the two underlined values. E.g. significance in CD56bright/CD16- NK cells between t0 and t1 is *p<=0.05
  2. Composition of NK cell subsets (CD56/CD16) in % (mean value ± standard deviation) in healthy controls (Ctrl, n = 22) and non-recurrent patients (n = 23) before (t0), after application of 20–30 Gy (t1), 3 months (t2) and 6 months (t3) after RCT. Significantly different values (t0 vs. t1; Ctrl vs. t0; t0 vs. t2) are indicated in bold with an asterisk (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)